[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201407676VA - A dry powder formulation - Google Patents

A dry powder formulation

Info

Publication number
SG11201407676VA
SG11201407676VA SG11201407676VA SG11201407676VA SG11201407676VA SG 11201407676V A SG11201407676V A SG 11201407676VA SG 11201407676V A SG11201407676V A SG 11201407676VA SG 11201407676V A SG11201407676V A SG 11201407676VA SG 11201407676V A SG11201407676V A SG 11201407676VA
Authority
SG
Singapore
Prior art keywords
dry powder
powder formulation
formulation
dry
powder
Prior art date
Application number
SG11201407676VA
Inventor
Desmond Heng
Lee Sie Huey
Jeanette Teo
Wai Kiong Ng
Reginald Tan
Original Assignee
Agency Science Tech & Res
Nat University Hospital Singapore Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res, Nat University Hospital Singapore Pte Ltd filed Critical Agency Science Tech & Res
Priority to SG11201407676VA priority Critical patent/SG11201407676VA/en
Publication of SG11201407676VA publication Critical patent/SG11201407676VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11201407676VA 2012-05-21 2013-05-21 A dry powder formulation SG11201407676VA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG11201407676VA SG11201407676VA (en) 2012-05-21 2013-05-21 A dry powder formulation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG2012037123 2012-05-21
SG11201407676VA SG11201407676VA (en) 2012-05-21 2013-05-21 A dry powder formulation
PCT/SG2013/000207 WO2013176622A1 (en) 2012-05-21 2013-05-21 A dry powder formulation

Publications (1)

Publication Number Publication Date
SG11201407676VA true SG11201407676VA (en) 2015-03-30

Family

ID=55167923

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407676VA SG11201407676VA (en) 2012-05-21 2013-05-21 A dry powder formulation

Country Status (3)

Country Link
US (1) US9707228B2 (en)
SG (1) SG11201407676VA (en)
WO (1) WO2013176622A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9707228B2 (en) 2012-05-21 2017-07-18 Agency For Science, Technology And Research Dry powder formulation
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US10149823B2 (en) 2013-04-30 2018-12-11 Otitopic Inc. Dry powder formulations and methods of use
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
JP7493449B2 (en) 2017-09-22 2024-05-31 ヴェクチュラ インコーポレイテッド Dry Powder Compositions Comprising Magnesium Stearate
US11110085B2 (en) * 2018-04-26 2021-09-07 Purdue Research Foundation Co-spray drying of ciprofloxacin and colistin and the uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI310688B (en) * 1999-10-29 2009-06-11 Nektar Therapeutics Dry powder compositions having improved dispersivity
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
MX359219B (en) 2005-05-18 2018-09-19 Raptor Pharmaceuticals Inc Aerosolized fluoroquinolones and uses thereof.
US20060280691A1 (en) * 2005-06-13 2006-12-14 University Of Alberta Spray freeze dried liposomal ciprofloxacin powder aerosol drug delivery
US8119156B2 (en) * 2006-10-24 2012-02-21 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
GB0719518D0 (en) * 2007-10-05 2007-11-14 Therapeutics Ltd E Therapy
WO2010111641A2 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
WO2011049960A2 (en) * 2009-10-21 2011-04-28 Otonomy, Inc. Compositions and methods for the treatment of sinonasal disorders
US9707228B2 (en) 2012-05-21 2017-07-18 Agency For Science, Technology And Research Dry powder formulation

Also Published As

Publication number Publication date
WO2013176622A1 (en) 2013-11-28
US9707228B2 (en) 2017-07-18
US20150132386A1 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
HK1204989A1 (en) Inhalable dry powders
HK1218405A1 (en) Dry sprinkler
EP2747815A4 (en) Dry powder inhalation device
EP2890621A4 (en) Powder dispenser
GB201215410D0 (en) A hand drier
HK1202445A1 (en) New formulation
SG11201407676VA (en) A dry powder formulation
ZA201306000B (en) Stable formulation
SG11201504134SA (en) External preparation
EP2857421A4 (en) Cellulose powder
HK1205679A1 (en) Nicotine formulation
HUE045020T2 (en) A novel stable formulation
PL2898027T3 (en) Paint formulations
HK1199380A1 (en) Rotary applicator
HK1207290A1 (en) Oral formulation
HK1206989A1 (en) Encapsulated formulation
PL2939661T3 (en) Novel microgranular formulation
GB201211247D0 (en) Improved formulation
GB201203383D0 (en) Powder
EP2867313A4 (en) A thermoset powder coating composition
IL234771B (en) Nicotine formulation
GB201207442D0 (en) Powder ball
GB201313909D0 (en) Powder formulation
GB201304145D0 (en) Powder formulation
GB201304146D0 (en) Powder formulation